Overview Markets Watchlist

© 2026 IR SuperintelMethodology Contact

Moonlake Immunotherapeutics

CUSIP: 61559X954 | 8 institutional holders

Quarters

Q3 2026 Q2 2026 Q1 2026 Q4 2025 Q3 2025

Compare Detailed Historical Funds Options Short Interest 13D/13G Peers Targeting Trading Summary Profile